Journal ArticleDOI
Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.
Katalin Kelemen,Leonie Saft,Fiona E. Craig,Attilio Orazi,Megan O. Nakashima,Gerald Wertheim,Tracy I. George,Hans-Peter Horny,Rebecca L. King,Leticia Quintanilla-Martinez,Sa A. Wang,Lisa M. Rimsza,Kaaren K. Reichard +12 more
Reads0
Chats0
TLDR
The most frequent diagnosis was reactive eosinophilia (35), followed by acute leukemia (24) and myeloproliferative neoplasms (MPNs) as mentioned in this paper.Abstract:
Objectives To report the findings of the 2019 Society for Hematopathology/European Association for Haematopathology Workshop within the categories of reactive eosinophilia, hypereosinophilic syndrome (HES), germline disorders with eosinophilia (GDE), and myeloid and lymphoid neoplasms associated with eosinophilia (excluding entities covered by other studies in this series). Methods The workshop panel reviewed 109 cases, assigned consensus diagnosis, and created diagnosis-specific sessions. Results The most frequent diagnosis was reactive eosinophilia (35), followed by acute leukemia (24). Myeloproliferative neoplasms (MPNs) received 17 submissions, including chronic eosinophilic leukemia, not otherwise specified (CEL, NOS). Myelodysplastic syndrome (MDS), MDS/MPN, and therapy-related myeloid neoplasms received 11, while GDE and HES received 12 and 11 submissions, respectively. Conclusions Hypereosinophilia and HES are defined by specific clinical and laboratory criteria. Eosinophilia is commonly reactive. An acute leukemic onset with eosinophilia may suggest core-binding factor acute myeloid leukemia, blast phase of chronic myeloid leukemia, BCR-ABL1-positive leukemia, or t(5;14) B-lymphoblastic leukemia. Eosinophilia is rare in MDS but common in MDS/MPN. CEL, NOS is a clinically aggressive MPN with eosinophilia as the dominant feature. Bone marrow morphology and cytogenetic and/or molecular clonality may distinguish CEL from HES. Molecular testing helps to better subclassify myeloid neoplasms with eosinophilia and to identify patients for targeted treatments.read more
Citations
More filters
Journal ArticleDOI
International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data.
Daniel A. Arber,Attilio Orazi,Robert P. Hasserjian,Michael Horowitz,Katherine R. Calvo,Hans Michael Kvasnicka,Sa A. Wang,Adam Bagg,Tiziano Barbui,Susan Branford,Carlos E. Bueso-Ramos,Jorge E. Cortes,Paola Dal Cin,Courtney D. DiNardo,Hervé Dombret,Eric J. Duncavage,Benjamin L. Ebert,Elihu H. Estey,Fabio Facchetti,Kathryn Foucar,Naseema Gangat,Umberto Gianelli,Lucy A. Godley,Nicola Goekbuget,Jason Gotlib,Eva Hellström-Lindberg,Gabriela S. Hobbs,Roald Hoffmann,Elias Jabbour,Jean-Jacques Kiladjian,Richard A. Larson,Michelle M. Le Beau,Mignon L. Loh,Bob Löwenberg,Elizabeth Macintyre,Luca Malcovati,Charles G. Mullighan,Charlotte M. Niemeyer,Olatoyosi Odenike,Seishi Ogawa,Alberto Orfao,Elli Papaemmanuil,Francesco Passamonti,Kimmo Porkka,C H Pui,Jerald P. Radich,Andreas Reiter,María Rozman,Martina Rudelius,Michael R. Savona,Charles A. Schiffer,Annette Schmitt-Graeff,Akiko Shimamura,Jorge Sierra,Wendy Stock,Richard Stone,Martin S. Tallman,Juergen Thiele,Hwei-Fang Tien,Alexandar Tzankov,Alessandro M. Vannucchi,Paresh Vyas,Andrew H. Wei,Olga Weinberg,Agnieszka Wierzbowska,Mario Cazzola,Hartmut Döhner,Ayalew Tefferi +67 more
TL;DR: The authors, a group with expertise in the clinical, pathologic and genetic aspects of these disorders, developed the International Consensus Classification (ICC), aimed at facilitating diagnosis and prognostication of these neoplasms, improving treatment of affected patients, and allowing the design of innovative clinical trials.
Journal ArticleDOI
Updates on eosinophilic disorders
Alexandar Tzankov,Kaaren K. Reichard,Robert P. Hasserjian,Daniel A. Arber,Attilio Orazi,Sa A. Wang +5 more
TL;DR: Bone marrow morphology now constitutes one of the diagnostic criteria of chronic eosinophilic leukemia, NOS, and idiopathic hypereos inophilia/hypereosinophile syndrome (HE/HES), facilitating the separation of a true myeloid neoplasm with characteristic eosInophilic proliferation from those of unknown etiology and not attributable to a myeloids.
Journal ArticleDOI
Chronic eosinophilic leukemia with recurrent STAT5B N642H mutation-An entity with features of myelodysplastic syndrome/ myeloproliferative neoplasm overlap.
Sreejesh Sreedharanunni,Manu Jamwal,Anand Balakrishnan,Arun Vijayalakshmi Aravindan,Ritika Sharma,Namrata Singh,Sweta Rajpal,Shelly Singla,Alka Khadwal,Jasmina Ahluwalia,Pankaj Malhotra,Reena Das +11 more
Journal ArticleDOI
Chronic eosinophilic leukemia with recurrent STAT5B N642H mutation—An entity with features of myelodysplastic syndrome/ myeloproliferative neoplasm overlap
Book ChapterDOI
Myeloid/Lymphoid Neoplasms with Eosinophilia and Platelet Derived Growth Factor Receptor Alpha (PDGFRA) Rearrangement
TL;DR: In this paper , practical issues regarding diagnosis, cytogenetic testing, molecular studies, therapeutics, and clinical implications are discussed, as well as different diagnosis in consideration for eosinophilia and hypererosinophilic syndrome are further highlighted.
References
More filters
Book
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
TL;DR: Thank you very much for reading who classification of tumours of haematopoietic and lymphoid tissues, and maybe you have knowledge that, people have look hundreds of times for their chosen readings like this, but end up in malicious downloads.
Journal ArticleDOI
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber,Attilio Orazi,Robert P. Hasserjian,Jürgen Thiele,Michael J. Borowitz,Michelle M. Le Beau,Clara D. Bloomfield,Mario Cazzola,James W. Vardiman +8 more
TL;DR: The 2016 edition of the World Health Organization classification of tumors of the hematopoietic and lymphoid tissues represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition.
Journal ArticleDOI
STAT3 Mutations in the Hyper-IgE Syndrome
Steven M. Holland,Frank R. DeLeo,Houda Elloumi,Amy P. Hsu,Gulbu Uzel,Nina N. Brodsky,Alexandra F. Freeman,Andrew P. Demidowich,Joie Davis,Maria L. Turner,Victoria L. Anderson,Dirk Darnell,Pamela Welch,Douglas B. Kuhns,David M. Frucht,Harry L. Malech,John I. Gallin,Scott D. Kobayashi,Adeline R. Whitney,Jovanka M. Voyich,James M. Musser,Cristina Woellner,Alejandro A. Schäffer,Jennifer M. Puck,Bodo Grimbacher +24 more
TL;DR: Mutations in STAT3 underlie sporadic and dominant forms of the hyper-IgE syndrome, an immunodeficiency syndrome involving increased innate immune response, recurrent infections, and complex somatic features.
Journal ArticleDOI
Type 2 innate lymphoid cells control eosinophil homeostasis
Jesse C. Nussbaum,Steven J. Van Dyken,Jakob von Moltke,Laurence E. Cheng,Alexander Mohapatra,Ari B. Molofsky,Emily E. Thornton,Matthew F. Krummel,Ajay Chawla,Hong-Erh Liang,Richard M. Locksley +10 more
TL;DR: It is shown that serum IL-5 levels are maintained by long-lived type 2 innate lymphoid cells (ILC2) resident in peripheral tissues, and this dissociated regulation can be tuned by nutrient intake and central circadian rhythms.
Journal Article
IL-4 is required to generate and sustain in vivo IgE responses.
Fred D. Finkelman,Ildy M. Katona,Joseph F. Urban,J M Holmes,J Ohara,A S Tung,J V Sample,William E. Paul +7 more
TL;DR: It is shown that IL-4 has an important role in sustaining established IgE responses, because anti-IL-4 antibody, when given at the peak of an N. brasiliensis- or TNP-keyhole limpet hemocyanin-induced IgE response, accelerates the declines in total serum IgE and in IgE anti-TNP antibody levels, respectively.